gem7 Antibody

What is gem7/GEMIN7 and what cellular functions do these proteins perform?

GEMIN7 (also known as Gemin-7 or SIP3) is a component of the core SMN (Survival Motor Neuron) complex required for pre-mRNA splicing in the nucleus. The protein is found in the nucleoplasm, in nuclear "gems" (Gemini of Cajal bodies), and in the cytoplasm . Three transcript variants encoding the same protein have been identified in humans .

In contrast, gem7 specifically refers to the orthologous protein in Schizosaccharomyces pombe (fission yeast) , representing an evolutionarily conserved component of RNA processing machinery.

The SMN complex performs critical functions in:

• Assembly of small nuclear ribonucleoproteins (snRNPs)

• Pre-mRNA splicing processes

• RNA metabolism regulation

What types of gem7/GEMIN7 antibodies are currently available for research?

Multiple antibody types targeting gem7/GEMIN7 are available for research applications, each with specific characteristics:

Most monoclonal antibodies target specific epitopes, while polyclonal antibodies recognize multiple epitopes, providing different advantages depending on experimental needs .

How should researchers select the appropriate gem7/GEMIN7 antibody for their experimental system?

Selection should be methodically approached through:

• Define target species: Ensure antibody reactivity matches your experimental organism. For example, if working with yeast models, specifically choose anti-gem7 antibodies validated for S. pombe .

• Match applications: Select antibodies validated for your specific technique:

  • For Western blotting: Antibodies with demonstrated specificity in denatured conditions

  • For immunohistochemistry: Antibodies validated for fixed tissue samples

  • For immunoprecipitation: Antibodies with confirmed affinity for native conformations

• Consider epitope accessibility: For GEMIN7/gem7 research, note that the protein localizes to both cytoplasmic and nuclear compartments , so epitope accessibility in different cellular compartments may vary.

• Evaluate clonality needs: Monoclonal antibodies like clone 4H6 provide high specificity for the C-terminal region , while polyclonal antibodies offer broader epitope recognition.

• Review validation data: Recent studies highlight that approximately 50% of commercial antibodies fail to meet basic characterization standards . Request comprehensive validation data including knockout controls.

What validation methods should be employed to confirm gem7/GEMIN7 antibody specificity?

A recent YCharOS study examining 614 antibodies targeting 65 proteins revealed that ~12 publications per protein target included data from antibodies that failed to recognize the relevant target protein . To avoid such issues:

• Knockout/knockdown controls: Essential for definitive validation of specificity, particularly for immunofluorescence imaging . Generate GEMIN7/gem7 knockouts or knockdowns in your experimental system.

• Immunoblotting profile: Verify detection of a protein band at the expected molecular weight (~35.9 kDa for human GEMIN7) with minimal non-specific binding.

• Peptide competition assays: Pre-incubating the antibody with the immunizing peptide should eliminate specific signals.

• Cross-reactivity assessment: If working across multiple species, verify species-specific reactivity experimentally rather than relying on vendor claims.

• Multi-antibody concordance: Compare results using antibodies targeting different epitopes of GEMIN7/gem7 (e.g., N-terminal vs. C-terminal antibodies).

What are the optimal protocols for using gem7/GEMIN7 antibodies in Western blot applications?

For successful detection of gem7/GEMIN7 proteins:

• Sample preparation:

  • For nuclear protein enrichment: Use fractionation methods to concentrate the SMN complex

  • Optimal lysis buffer: Phosphate buffered solution with protease inhibitors

  • Denaturation: 5 minutes at 95°C in reducing sample buffer

• Protein loading and separation:

  • Recommended loading: 20-30 μg total protein per lane

  • Gel percentage: 12-15% acrylamide gels provide optimal separation

• Transfer and blocking:

  • Transfer time: 1 hour at 100V for wet transfer systems

  • Blocking: 5% non-fat milk in TBST (1 hour at room temperature)

• Antibody incubation:

  • Primary antibody dilution: 1-5 μg/mL for monoclonal anti-GEMIN7

  • Incubation: Overnight at 4°C for optimal signal-to-noise ratio

  • Secondary antibody: HRP-conjugated anti-mouse or anti-rabbit IgG (1:5000)

• Detection and visualization:

  • Enhanced chemiluminescence is recommended

  • Expected molecular weight: ~35.9 kDa for human GEMIN7

How can GEMIN7/gem7 antibodies be used to investigate protein-protein interactions in the SMN complex?

The GEMIN7 protein functions within the SMN complex, which is crucial for pre-mRNA splicing . To investigate these interactions:

• Co-immunoprecipitation (Co-IP):

  • Use 4H6 monoclonal antibody or other IP-validated antibodies

  • Cross-link antibodies to beads to prevent IgG contamination

  • Include appropriate negative controls (IgG isotype control)

  • Analyze precipitates for known SMN complex components

• Proximity ligation assays (PLA):

  • Enables visualization of protein interactions in situ

  • Combine anti-GEMIN7 with antibodies against other SMN complex components

  • PLA signal indicates proteins are within 40 nm of each other

• Immunofluorescence co-localization:

  • Focus on nuclear "gems" (Gemini of Cajal bodies) where GEMIN7 localizes

  • Use confocal microscopy for high-resolution co-localization analysis

• Domain mapping considerations:

  • The anti-GEMIN7 monoclonal antibody 4H6 targets the C-terminal region

  • For domain interaction studies, consider antibodies targeting different epitopes

What considerations are important when using gem7/GEMIN7 antibodies across different species?

Sequence homology analysis for GEMIN7 shows varying conservation across species:

• Cow: 86%

• Dog, Guinea Pig, Horse, Mouse: 93%

• Rat: 100% homology to human

For cross-species applications:

• Epitope conservation analysis: Compare the antibody's target sequence across species before application. For the polyclonal antibody in search result , the peptide sequence "MQTPVNIPVP VLRLPRGPDG FSRGFAPDGR RAPLRPEVPE IQECPIAQES" shows high conservation.

• Validation in each species: Even with high sequence homology, empirical validation is essential. The YCharOS study demonstrated antibody performance varies significantly across applications .

• Yeast studies: For S. pombe research, use antibodies specifically raised against yeast gem7 , as mammalian GEMIN7 antibodies may not cross-react.

• Optimization for each species: Adjust antibody concentrations, incubation times, and detection methods for each species.

How should researchers troubleshoot non-specific binding or high background when using gem7/GEMIN7 antibodies?

If encountering technical difficulties:

• Antibody dilution optimization:

  • Start with manufacturer's recommended dilution

  • Perform a dilution series (e.g., 1:100, 1:500, 1:1000)

  • For Western blots with anti-GEMIN7 (C-terminal), try 1-5 μg/mL range

• Blocking optimization:

  • Test alternative blocking agents (BSA, commercial blockers)

  • Increase blocking time (2-3 hours at room temperature)

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

• Washing protocol enhancement:

  • Increase wash steps (5-6 washes)

  • Extend wash durations (10-15 minutes each)

  • Use fresh washing buffers

• Sample preparation refinement:

  • Use phosphatase inhibitors to prevent post-translational modifications

  • For nuclear proteins like GEMIN7, optimize nuclear extraction protocols

  • Filter lysates to remove particulates causing non-specific binding

• Secondary antibody selection:

  • Use highly cross-adsorbed secondary antibodies

  • Consider fluorescent secondaries for lower background in some applications

What approaches can be used to study post-translational modifications of gem7/GEMIN7?

To investigate post-translational modifications (PTMs):

• Antibody selection:

  • Use antibodies targeting unmodified epitopes for total protein detection

  • Consider developing modification-specific antibodies if PTMs are identified

• Sample preparation:

  • Include appropriate inhibitors (phosphatase, deacetylase, etc.)

  • For phosphorylation studies, treat samples with λ-phosphatase as controls

• Enrichment strategies:

  • Immunoprecipitate GEMIN7 followed by PTM-specific Western blotting

  • Consider phospho-enrichment methods for phosphorylation studies

• Mass spectrometry integration:

  • Immunoprecipitate GEMIN7 using validated antibodies

  • Submit samples for PTM mapping by mass spectrometry

  • Validate identified PTMs using site-directed mutagenesis

• Functional analysis:

  • Correlate identified PTMs with SMN complex formation efficiency

  • Assess impact on pre-mRNA splicing activity

What are the best practices for quantification when using gem7/GEMIN7 antibodies in research?

For accurate quantification:

• Standardization approaches:

  • Use recombinant GEMIN7 protein standards for absolute quantification

  • Include loading controls appropriate for your experimental system

  • For nuclear proteins like GEMIN7, use nuclear-specific loading controls

• Image acquisition considerations:

  • Avoid saturated signals which prevent accurate quantification

  • Capture multiple exposure times to ensure linearity

  • Use the same acquisition settings across comparable samples

• Software and analysis:

  • Apply consistent region-of-interest selection methods

  • Subtract local background for each measurement

  • Normalize to appropriate loading controls

• Statistical analysis:

  • Perform biological replicates (minimum n=3) with technical duplicates

  • Apply appropriate statistical tests based on data distribution

  • Report confidence intervals along with means

• Reporting standards:

  • Document key experimental details including antibody catalog numbers, dilutions, and lot numbers

  • Include representative images of entire blots/fields

  • Report antibody validation methods used

How can artificial intelligence approaches be integrated with antibody-based detection of gem7/GEMIN7?

Recent advances in AI applied to antibody technology can enhance gem7/GEMIN7 research:

• AI-assisted antibody design:

  • Pre-trained Antibody generative large Language Models (PALM-H3) can generate antibodies with desired antigen-binding specificity

  • A2binder models can predict binding specificity and affinity between antigen epitopes and antibody sequences

• Validation and quality assessment:

  • AI models can help predict cross-reactivity profiles based on antibody sequence

  • Enable assessment of antibody performance across different applications

• Image analysis enhancement:

  • Machine learning algorithms improve signal-to-noise discrimination

  • Enable automated quantification in complex immunofluorescence images

  • Help standardize region-of-interest selection

• Sequence analysis applications:

  • Identify conserved epitopes across species for antibody target selection

  • For GEMIN7/gem7, AI methods could identify evolutionarily conserved functional domains

A recent study demonstrated successful application of AI methods for generating antibodies targeting SARS-CoV-2 variants, suggesting similar approaches could enhance antibody reagents for GEMIN7 research .

What are the implications of GEMIN7 V-gene allelic polymorphisms for antibody recognition?

Recent research has revealed that immunoglobulin V-gene allelic polymorphisms significantly impact antibody generation and binding capabilities:

• Polymorphism impact assessment:

  • V-gene allelic polymorphisms in antibody paratopes can determine binding activity

  • Biolayer interferometry experiments demonstrate polymorphisms on both heavy and light chains can abolish antibody binding

• Experimental considerations:

  • When developing antibodies against GEMIN7, consider the impact of V-gene polymorphisms

  • Verify antibody performance across different genetic backgrounds

• Cross-reactivity implications:

  • Polymorphisms may affect cross-reactivity with GEMIN7 orthologs

  • Multiple antibodies targeting different epitopes may be needed for comprehensive detection

• Validation requirements:

  • Test GEMIN7 antibodies against variant protein sequences

  • Consider establishing a panel of antibodies that collectively recognize all relevant variants